{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T05:09:29Z","timestamp":1721452169832},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2020-0587_abs_001_w2aab3b7c61b1b6b1aab1c15b1Aa\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The development of continuous glucose monitoring (CGM) systems has allowed for identification of blood sugar variations and trends in real-time that is not feasible with conventional self-monitoring of blood glucose. However, there is inconsistent data to show that the use of CGM leads to better glycemic control as measured by Hemoglobin A1c (HbA1c) in pediatric patients with type 1 diabetes mellitus. Our study aimed to compare the average HbA1c level in the 1\u20132 years prior to starting a CGM to the average HbA1c level in the 1\u20132 years immediately following CGM initiation in a sample of 1\u201320 year olds with type 1 diabetes mellitus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0587_abs_002_w2aab3b7c61b1b6b1aab1c15b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were 90 youth (ages 1\u201320) followed for type 1 diabetes care at our institution who used a CGM for at least a 6\u00a0month time period. We performed a retrospective chart review to obtain up to four HbA1c values pre and post-CGM initiation each. We evaluated pre- and post-CGM initiation changes in mean HbA1c via dependent samples t-tests using IBM SPSS 24.0.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0587_abs_003_w2aab3b7c61b1b6b1aab1c15b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean HbA1c was 8.7% pre-CGM and decreased to 8.27% 9\u201312\u00a0months after CGM initiation in the overall sample. A statistically significant decrease in HbA1c was seen in patients who used multiple daily injections (p=0.02), those with a pre-CGM HbA1c greater than 9% (p=0.01), and those with a diabetes duration of 5\u201310 years (p=0.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0587_abs_004_w2aab3b7c61b1b6b1aab1c15b4Aa\">\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CGM use was associated with a decrease in HbA1c over time which was statistically significant in some subgroups.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2020-0587","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T22:27:07Z","timestamp":1614032827000},"page":"311-317","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Hemoglobin A1c before and after initiation of continuous glucose monitoring in children with type 1 diabetes mellitus"],"prefix":"10.1515","volume":"34","author":[{"given":"Shilpa","family":"Gurnurkar","sequence":"first","affiliation":[{"name":"Nemours Children\u2019s Hospital , Orlando , FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Owens","sequence":"additional","affiliation":[{"name":"University of Central Florida, College of Medicine , Orlando , FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sweta","family":"Chalise","sequence":"additional","affiliation":[{"name":"University of Central Florida, College of Medicine , Orlando , FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Vyas","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Hospital , Orlando , FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"2023040101391766126_j_jpem-2020-0587_ref_001_w2aab3b7c61b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Nathan, DM, Genuth, S, Lachin, J, Cleary, P, Crofford, O, Davis, M, et al.. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977\u201386. https:\/\/doi.org\/10.1056\/NEJM199309303291401.","DOI":"10.1056\/NEJM199309303291401"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_002_w2aab3b7c61b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Wright, LA, Hirsch, IB. Metrics beyond Hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol Ther 2017;19(Suppl 2):S16\u2013s26. https:\/\/doi.org\/10.1089\/dia.2017.0029.","DOI":"10.1089\/dia.2017.0029"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_003_w2aab3b7c61b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Burge, MR, Mitchell, S, Sawyer, A, Schade, DS. Continuous glucose monitoring: the future of. Diabetes Manag 2008;21:112\u20139. https:\/\/doi.org\/10.2337\/diaspect.21.2.112.","DOI":"10.2337\/diaspect.21.2.112"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_004_w2aab3b7c61b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Wadwa, RP, Laffel, LM, Shah, VN, Garg, SK. Accuracy of a factory-calibrated, real-time continuous glucose monitoring system during 10\u00a0days of use in youth and adults with diabetes. Diabetes Technol Ther 2018;20:395\u2013402. https:\/\/doi.org\/10.1089\/dia.2018.0150.","DOI":"10.1089\/dia.2018.0150"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_005_w2aab3b7c61b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Deiss, D, Hartmann, R, Schmidt, J, Kordonouri, O. Results of a randomised controlled cross-over trial on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycaemic control in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2006;114:63\u20137. https:\/\/doi.org\/10.1055\/s-2006-923887.","DOI":"10.1055\/s-2006-923887"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_006_w2aab3b7c61b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Tamborlane, WV, Beck, RW, Bode, BW, Buckingham, B, Chase, HP, Clemons, R, et al.. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464\u201376. https:\/\/doi.org\/10.1056\/NEJMoa0805017.","DOI":"10.1056\/NEJMoa0805017"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_007_w2aab3b7c61b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Mauras, N, Beck, R, Xing, D, Ruedy, K, Buckingham, B, Tansey, M, et al.. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. Diabetes Care 2012;35:204\u201310. https:\/\/doi.org\/10.2337\/dc11-1746.","DOI":"10.2337\/dc11-1746"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_008_w2aab3b7c61b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Tsalikian, E, Fox, L, Weinzimer, S, Buckingham, B, White, NH, Beck, R, et al.. Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatr Diabetes 2012;13:301\u20137. https:\/\/doi.org\/10.1111\/j.1399-5448.2011.00837.x.","DOI":"10.1111\/j.1399-5448.2011.00837.x"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_009_w2aab3b7c61b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Dicembrini, I, Pala, L, Caliri, M, Minardi, S, Cosentino, C, Monami, M, et al.. Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: a randomized crossover trial. Diabetes Obes Metab 2020;22:1286\u201391. https:\/\/doi.org\/10.1111\/dom.14028.","DOI":"10.1111\/dom.14028"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_010_w2aab3b7c61b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Kaufman, FR, Gibson, LC, Halvorson, M, Carpenter, S, Fisher, LK, Pitukcheewanont, P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001;24:2030\u20134. https:\/\/doi.org\/10.2337\/diacare.24.12.2030.","DOI":"10.2337\/diacare.24.12.2030"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_011_w2aab3b7c61b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Chase, HP, Beck, RW, Xing, D, Tamborlane, WV, Coffey, J, Fox, LA, et al.. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Technol Ther 2010;12:507\u201315. https:\/\/doi.org\/10.1089\/dia.2010.0021.","DOI":"10.1089\/dia.2010.0021"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_012_w2aab3b7c61b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Laffel, L. Improved accuracy of continuous glucose monitoring systems in pediatric patients with diabetes mellitus: results from two studies. Diabetes Technol Ther 2016;18(Suppl 2):S223\u201333. https:\/\/doi.org\/10.1089\/dia.2015.0380.","DOI":"10.1089\/dia.2015.0380"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_013_w2aab3b7c61b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Sacks, DB. Hemoglobin A1c in diabetes: panacea or pointless? Diabetes 2013;62:41\u20133. https:\/\/doi.org\/10.2337\/db12-1485.","DOI":"10.2337\/db12-1485"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_014_w2aab3b7c61b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Bergenstal, RM, Gal, RL, Beck, RW. Racial differences in the relationship of glucose concentrations and Hemoglobin A1c levels. Ann Intern Med 2018;168:232\u20133. https:\/\/doi.org\/10.7326\/l17-0589.","DOI":"10.7326\/L17-0589"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_015_w2aab3b7c61b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Herman, WH, Ma, Y, Uwaifo, G, Haffner, S, Kahn, SE, Horton, ES, et al.. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007;30:2453\u20137. https:\/\/doi.org\/10.2337\/dc06-2003.","DOI":"10.2337\/dc06-2003"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_016_w2aab3b7c61b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Battelino, T, Danne, T, Bergenstal, RM, Amiel, SA, Beck, R, Biester, T, et al.. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593\u2013603. https:\/\/doi.org\/10.2337\/dci19-0028.","DOI":"10.2337\/dci19-0028"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_017_w2aab3b7c61b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Danne, T, Nimri, R, Battelino, T, Bergenstal, RM, Close, KL, DeVries, JH, et al.. International consensus on use of continuous glucose monitoring. Diabetes Care 2017;40:1631\u201340. https:\/\/doi.org\/10.2337\/dc17-1600.","DOI":"10.2337\/dc17-1600"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_018_w2aab3b7c61b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Beck, RW, Hirsch, IB, Laffel, L, Tamborlane, WV, Bode, BW, Buckingham, B, et al.. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378\u201383. https:\/\/doi.org\/10.2337\/dc09-0108.","DOI":"10.2337\/dc09-0108"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_019_w2aab3b7c61b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Sherr, JL, Tauschmann, M, Battelino, T, de Bock, M, Forlenza, G, Roman, R, et al.. ISPAD clinical practice consensus guidelines 2018: diabetes technologies. Pediatr Diabetes 2018;19(Suppl 27):302\u201325. https:\/\/doi.org\/10.1111\/pedi.12731.","DOI":"10.1111\/pedi.12731"},{"key":"2023040101391766126_j_jpem-2020-0587_ref_020_w2aab3b7c61b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Beck, RW, Bergenstal, RM, Riddlesworth, TD, Kollman, C, Li, Z, Brown, AS, et al.. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 2019;42:400\u20135. https:\/\/doi.org\/10.2337\/dc18-1444.","DOI":"10.2337\/dc18-1444"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0587\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T21:22:17Z","timestamp":1680384137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0587\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2,22]]},"published-print":{"date-parts":[[2021,3,26]]}},"alternative-id":["10.1515\/jpem-2020-0587"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2020-0587","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,23]]}}}